Global Mental Health Clinical Trials Market Size study & Forecast, by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional, Observational, Expanded Access) by Sponsor (Pharmaceutical & Biopharmaceutical Companies, Government Agencies, Others), by Disorder (Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation and dissociative disorders, Schizophrenia, Others) and Regional Analysis, 2022-2029
Global Mental Health Clinical Trials Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. This are the clinics which deals with mental health problems. Throughout the course of the projection period, it is predicted that the global market for mental health clinical trials would expand significantly. The incidence of mental health illnesses, public awareness of mental health conditions, and increased funding from government agencies, businesses, hospitals, and universities are the main reasons driving the market's expansion. Moreover, rising number of mental illness and initiative by key market players are creating lucrative growth opportunity for the market over the forecast period.
Significant disruptions in thought, behavior, or emotional regulation characterize mental illnesses. According to a recent WHO report, 1 in every 8 people worldwide will have a mental condition in 2022. The two most prevalent mental illnesses, sadness, and anxiety, affected 970 million individuals worldwide in 2019.Worry, excessive fear, and accompanying behavioral abnormalities are hallmarks of anxiety disorders. According to 2019 WHO estimate, 58.0 million of the 301.0 million people with anxiety disorders are children and adolescents. There are numerous varieties of anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. According to a scientific analysis by the WHO, the Covid-19 pandemic increased the prevalence of anxiety and depression globally by 25%. Stress brought on by the pandemic's social isolation is a significant factor. Depression and anxiety are caused by a variety of fears, including those of illness, pain, loneliness, money worries, and mourning following a loss. However, the high cost of Mental Health Clinical Trials stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Mental Health Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Due to factors similar to increased R&D spending, supportive government policies, and growth in the use of innovative technologies in clinical trials, North America is predicted to have the largest market share throughout the projection period. Clinicaltrials.org reports that from 2019 to 2021, 52% of all registered clinical trials for depression would be conducted in the region. Also, from 2019 to 2021, the region's trial percentage will rise from 45.9% to 50.9%. Along with this, Asia-Pacific is growing with the fastest CAGR over the forecast period owing to the rising number of clinical trials.
Major market player included in this report are:
ICON Plc.
Eli Lilly and Company
Caidya
Syneous Health
Novo Nordisk AS
Pharmaceutical Product Development, LLC
Parexel International Corporation
Corcept Therapeutics Incorporated (Corcept)
Labcorp Drug Development
IQVIA, Inc.
Recent Developments in the Market:
In September 2022, the launch of Epic's Life Sciences division broadens its efforts to reunite the fragmented elements of the healthcare system. The goals of the program is to include facilitating the recruitment of research participants, accelerating the development of novel treatments for providers, and increasing access to clinical trials for underrepresented populations, pharmaceutical firms, and medical device manufacturers.
Global Mental Health Clinical Trials Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Study Design, Sponsor, Disorder, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Study Design offerings of key players.
The detailed segments and sub-segment of the market are explained below:
By Phase:
Phase I
Phase II
Phase III
Phase IV
By Study Design:
Interventional
Observational
Expanded Access
By Sponsor:
Pharmaceutical & Biopharmaceutical Companies
Government Agencies
Others
By Disorder:
Anxiety Disorders
Depression
Bipolar affective disorder
Dissociation and dissociative disorders
Schizophrenia
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Companies Mentioned
ICON Plc.
Eli Lilly and Company
Caidya
Syneous Health
Novo Nordisk AS
Pharmaceutical Product Development, LLC
Parexel International Corporation
Corcept Therapeutics Incorporated (Corcept)
Labcorp Drug Development
IQVIA, Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook